GENE ONLINE|News &
Opinion
Blog

Hemophilia A
FDA Approves Sanofi and Sobi’s Once-Weekly Hemophilia A Med
2023-02-23
Pfizer, Sangamo Re-Opens Enrolment For Hemophilia A Gene Therapy
2022-09-26
Sanofi’s Treatment for Hemophilia A has a Concrete FDA Decision Date
2022-08-30
Takeda Inks $3.6 Billion Deal with Poseida to Advance Non-Viral Gene Therapies and Overcome Safety Issues
2021-10-13
The Transformative Potential of Gene Therapies for Hemophilia
2021-04-08
Pfizer, Sangamo Dose First Hemophilia A Patient in Phase 3 with Gene Therapy Candidate
2020-10-08
FDA Rejects BioMarin Pharmaceuticals’ Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
2020-08-20
Sangamo’s Shares Goes up after the Announcement of Investigational Hemophilia A Gene Therapy Results
2019-07-19
Emicizumab promises weekly/biweekly prophylaxis in hemophilia-A patients
2018-09-04
LATEST
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
EVENT
Scroll to Top